Table 1 Results from analyses of samples
From: Clinical effects of adsorption of lipopolysaccharide in the treatment of Gram-negative severe sepsis
| Â | Stage | |||||||
|---|---|---|---|---|---|---|---|---|
| Â | I | II | III | IV | ||||
Parameter | RefG | AdG | RefG | Adg | REfG | Adg | RefG | AdG |
LPS (EU/ml) | 1.4 ± 0.0 | 1.4 ± 0.0 | 1.4 ± 0.2 | 0.8 ± 0.2 | 1.4 ± 0.6 | 0.4 ± 0.3 | 1.4 ± 0.2 | 0.2 ± 0.0 |
PCT (ng/ml) | 15.6 ± 2.8 | 16.0 ± 2.5 | 16.4 ± 2.2 | 11.6 ± 3.7 | 14.3 ± 2.8 | 4.2 ± 2.2 | 13.6 ± 3.8 | 1.4 ± 0.9 |
CI (l/min/m2) | 2.7 ± 0.8 | 2.9 ± 0.7 | 2.9 ± 0.8 | 3.9 ± 0.9 | 3.1 ± 0.6 | 3.0 ± 0.7 | 2.9 ± 0.5 | 4.7 ± 1.9 |
MAP (mmHg) | 60.6 ± 4.3 | 59.1 ± 5.8 | 66.9 ± 5.5 | 79.7 ± 4.6 | 69.4 ± 1.4 | 81.1 ± 2.9 | 69.1 ± 3.2 | 83.8 ± 5.7 |
Pa2 (mmHg) | 88.2 ± 2.1 | 84.5 ± 12.1 | 89.9 ± 14.4 | 108.7 ± 16.1 | 88.3 ± 9.4 | 129.4 ± 12.2 | 91.7 ± 7.8 | 130.6 ± 9.2 |
FlO2 (%) | 60.0 ± 0.0 | 50.0 ± 4.1 | 50.0 ± 0.0 | 40.1 ± 4.3 | 50.0 ± 0.0 | 37.4 ± 3.5 | 50.0 ± 0.0 | 35.0 ± 0.0 |
ELWl (ml/kg) | 12.9 ± 3.3 | 13.2 ± 1.2 | 13.1 ± 2.2 | 9.2 ± 3.1 | 11.0 ± 2.7 | 7.1 ± 1.1 | 9.7 ± 2.1 | 4.3 ± 2.1 |
PAO2/FiO2 | 146.4 ± 12.1 | 168.4 ± 16.5 | 179.2 ± 10.1 | 270.1 ± 24.3 | 176.3 ± 9.5 | 345.0 ± 21.1 | 183.2 ± 12.1 | 373.5 ± 14.3 |
Dopamin (μg/kg/min) | 12.0 ± 1.7 | 13.3 ± 3.9 | 14.2 ± 2.2 | 8.1 ± 2.1 | 13.5 ± 3.1 | 3.3 ± 1.4 | 11.7 ± 1.9 | 3.1 ± 0.3 |
SaO2 (%) | 87.3 ± 2.2 | 86.7 ± 3.1 | 86.9 ± 1.9 | 94.9 ± 2.8 | 89.5 ± 3.5 | 98.2 ± 0.9 | 93.6 ± 5.4 | 98.5 ± 0.4 |
SVO2 venous (%) | 79.8 ± 2.5 | 80.0 ± 1.5 | 82.2 ± 2.3 | 76.0 ± 3.4 | 85.3 ± 3.1 | 71.3 ± 2.4 | 79.8 ± 2.9 | 72.8 ± 3.7 |
Lactate (mol/l) | 4.9 ± 2.1 | 4.8 ± 1.7 | 5.5 ± 1.3 | 3.2 ± 1.1 | 5.3 ± 1.3 | 2.4 ± 0.9 | 5.4 ± 0.9 | 1.7 ± 0.6 |
APTt (sec) | 41.5 ± 5.9 | 42.1 ± 4.6 | 46.6 ± 7.7 | 58.4 ± 5.7 | 48.8 ± 12.1 | 66.3 ± 8.5 | 50.2 ± 11.8 | 62.3 ± 3.4 |